clinical trial · NCT06655324
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Merck Sharp & Dohme LLC·phase1·recruiting·n = 250
HealthyV350AV350BPlacebo
brief summary
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
started
Dec 5, 2024
primary completion
Jul 17, 2028
completion
Jul 17, 2028
last updated
Apr 13, 2026
official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol